Stroma as an Active Player in the Development of the Tumor Microenvironment

Cancer Microenvironment

Volumn 8, Issue 3, 2015, Pages 159-166

  Vannucci, L ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

Author keywords

Fibrosis; LOX; Stiffness; TGF ; Tumor microenvironment; Tumor stroma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CALVASCULIN; CD4 ANTIGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERSTITIAL COLLAGENASE; KALLIKREIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; NITRIC OXIDE; ORNITHINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN C PROTEINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; UVOMORULIN; WNT PROTEIN; WNT10B PROTEIN; WNT3A PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RISK; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CROHN DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA; TISSUE REPAIR; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS;

EID: 84955204530     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-014-0150-x     Document Type: Article

References (88)

1. Pietras K, Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324–1331
2. Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC (2011) Tumor microenvironment is multifaceted. Cancer Metastasis Rev 30:13–25
3. Wu Y, Antony S, Meitzler JL, Doroshow JH (2013) Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett 345:164–173
4. Taipale J, Miyazono K, Heldin CH, Keski-Oja J (1994) Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 124:171–181
5. Unsöld C, Hyytiäinen M, Bruckner-Tuderman L, Keski-Oja J (2001) Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 114:187–197
6. Valenick LV, Hsia HC, Schwarzbauer JE (2005) Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp Cell Res 309:48–55
7. Wipff PJ, Hinz B (2008) Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol 87:601–615
8. Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX (2014) Matrikines from basement membrane collagens: A new anti-cancer strategy. Biochim Biophys Acta 1840:2589-2598
9. Egeblad M, Rasch MG, Weaver VM (2010) Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 22:697–706
10. Friedl P, Bröcker EB, Zänker KS (1998) Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Cell Adhes Commun 6:225–236
11. Friedl P, Bröcker EB (2000) T cell migration in three-dimensional extracellular matrix: guidance by polarity and sensations. Dev Immunol 7:249–266
12. Miles FL, Sikes RA (2014) Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 12:297–312
13. Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E (2013) Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci 70:4431–4448
14. Dvorak HF (1986) Tumors: wounds that do not heal. N Engl J Med 315:1650–1659
15. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
16. Cassetta L, Cassol E, Poli G (2011) Macrophage polarization in health and disease. Sci World J 11:2391–2402
17. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176–185
18. Davies LC, Jenkins SJ, Allen JE, Taylor PR (2013) Tissue-resident macrophages. Nat Immunol 14:986–995
19. Chambers SE, O’Neill CL, O’Doherty TM, Medina RJ, Stitt AW (2013) The role of immune-related myeloid cells in angiogenesis. Immunobiology 218:1370–1375
20. Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262–274
21. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56:1687–1700
22. Weidenbusch M, Anders HJ (2012) Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. J Innate Immun 4:463–477
23. Mantovani A (2012) MSCs, macrophages, and cancer: a dangerous ménage-à-trois. Cell Stem Cell 11:730–732
24. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A (2013) Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 228:1404–1412
25. Li B, Wang JH (2011) Fibroblasts and myofibroblasts in wound healing: force generation and measurement. J Tissue Viability 20:108–120
26. Polanska UM, Orimo A (2013) Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 228:1651–1657
27. Byun JS, Gardner K (2013) Wounds that will not heal: pervasive cellular reprogramming in cancer. Am J Pathol 182:1055–1064
28. Liguori M, Solinas G, Germano G, Mantovani A, Allavena P (2011) Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) 3:3740–3761
29. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83:1136–1144
30. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E (2013) The role of IL-1β in the early tumor cell-induced angiogenic response. J Immunol 190:3500–3509
31. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003–1018
32. Rider P, Carmi Y, Voronov E, Apte RN (2013) Interleukin-1α. Semin Immunol 25:430–438
33. Perrot CY, Javelaud D, Mauviel A (2013) Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Ann Dermatol 25:135–144
34. Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435–457
35. Petrella BL, Vincenti MP (2012) Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β. Cancer Med 1:17–27
36. Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211:19–26
37. Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, Watabe T, Komuro A, Kano MR, Miyazono K (2008) Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 111:4571–4579
38. Wong SF, Lai LC (2001) The role of TGFbeta in human cancers. Pathology 33:85–92
39. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (2012) TGF-β - an excellent servant but a bad master. J Transl Med 10:183
40. Pickup M, Novitskiy S, Moses HL (2013) The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13(11):788–799
41. Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, Hattori R, Matsukawa Y, Mizuno T, Noda Y, Nishimura H, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y (2013) TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol 24:1627–1642
42. Clavin NW, Avraham T, Fernandez J, Daluvoy SV, Soares MA, Chaudhry A, Mehrara BJ (2008) TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol 295:H2113–H2127
43. Ji RC (2006) Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25:677–694
44. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4 + CD25- T cells into CD4 + CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892
45. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM, Huang RP (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845:182–201
46. Horiguchi M, Ota M, Rifkin DB (2012) Matrix control of transforming growth factor-β function. J Biochem 152:321–329
47. Taipale J, Saharinen J, Keski-Oja J (1998) Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res 75:87–134
48. Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O (2014) Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol Oncol 8:68–82
49. Xiao Q, Ge G (2012) Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 5:261–273
50. Kim YM, Kim EC, Kim Y (2011) The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38:145–149
51. Cano A, Santamaría PG, Moreno-Bueno G (2012) LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol 8:1095–1108
52. Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V, Suss-Toby E, Adam D, Shaked Y, Smith V, Neufeld G (2013) Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 34:2370–2379
53. Barker HE, Bird D, Lang G, Erler JT (2013) Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol Cancer Res 11:1425–1436
54. Sion AM, Figg WD (2006) Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biol Ther 5:909–911
55. Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL (2013) Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res 73:5336–5346
56. Leask A, Hutchenreuther J (2014) Activation of latent TGFβ by α(v)β (1) integrin: of potential importance in myofibroblast activation in fibrosis. J Cell Commun Signal 8:171–172
57. Wipff PJ, Rifkin DB, Meister JJ, Hinz B (2007) Myofibroblast contraction activates latent TGF-β 1 from the extracellular matrix. J Cell Biol 179:1311–1323
58. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891–906
59. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3:349–363
60. Calon A, Tauriello DV, Batlle E (2014) TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25:15–22
61. Desmoulière A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12
62. Montesano R, Orci L (1988) Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci U S A 85:4894–4897
63. Buscemi L, Ramonet D, Klingberg F, Formey A, Smith-Clerc J, Meister JJ, Hinz B (2011) The single-molecule mechanics of the latent TGF-β1 complex. Curr Biol 21:2046–2054
64. Scharenberg MA, Pippenger BE, Sack R, Zingg D, Ferralli J, Schenk S, Martin I, Chiquet-Ehrismann R (2014) TGF-β-induced differentiation into myofibroblasts involves specific regulation of two MKL1 isoforms. J Cell Sci 127:1079–1091
65. Vi L, de Lasa C, DiGuglielmo GM, Dagnino L (2011) Integrin-linked kinase is required for TGF-β1 induction of dermal myofibroblast differentiation. J Investig Dermatol 131:586–593
66. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, Ding Q, Thannickal VJ, Zhou Y (2012) Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 47:340–348
67. Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM (2013) Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 504:277–281
68. Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, Sime PJ, Phipps RP (2006) More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Investig 35:297–325
69. Chien AJ, Conrad WH, Moon RT (2009) A Wnt survival guide: from flies to human disease. J Investig Dermatol 129:1614–1627
70. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149:1192–1205
71. Chen D, Jarrell A, Guo C, Lang R, Atit R (2012) Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development 139:1522–1533
72. O’Reilly S (2014) Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 126:329–337
73. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J (2012) Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 64:2734–2745
74. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH (2012) β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 71:761–767
75. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149:1192–1205
76. Kato S, Hayakawa Y, Sakurai H, Saiki I, Yokoyama S (2014) Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci 105:281–289
77. Díaz Prado SM, Medina Villaamil V, Aparicio Gallego G, Blanco Calvo M, López Cedrún JL, Sironvalle Soliva S, Valladares Ayerbes M, García Campelo R, Antón Aparicio LM (2009) Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas. Virchows Arch 455:67–75
78. Qurrat-Ul-Ain, Seemab U, Nawaz S, Rashid S (2011) Integrative analyses of conserved WNT clusters and their co-operative behaviour in human breast cancer. Bioinformation 7:339–46
79. Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak MS, Wolsky R, Bentolila LA, Grant SG, Elashoff D, Lehr S, Latimer JJ, Bose S, Sattar H, Krum SA, Miranda-Carboni GA (2013) WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 5:264–279
80. Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le Gonidec S, Couderc B, Escourrou G, Valet P, Muller C (2013) Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res 73:5657–5668
81. Kakudo N, Kushida S, Suzuki K, Ogura T, Notodihardjo PV, Hara T, Kusumoto K (2012) Effects of transforming growth factor-beta1 on cell motility, collagen gel contraction, myofibroblastic differentiation, and extracellular matrix expression of human adipose-derived stem cell. Hum Cell 25:87–95
82. 1 is increased in chronic obstructive pulmonary disease. PLoS One 6:e25450
83. van Dekken H, Wink JC, Vissers KJ, Franken PF (2007) Ruud Schouten W, J Hop WC, Kuipers EJ, Fodde R, Janneke van der Woude C. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem 109:266–272
84. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, Gopalan B, Stylianou E, Fiocchi C (2011) Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 179:2660–2673
85. Blaauboer ME, Emson CL, Verschuren L, van Erk M, Turner SM, Everts V, Hanemaaijer R, Stoop R (2013) Novel combination of collagen dynamics analysis and transcriptional profiling reveals fibrosis-relevant genes and pathways. Matrix Biol 32:424–431
86. Shih YR, Tseng KF, Lai HY, Lin CH, Lee OK (2011) Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. J Bone Miner Res 26:730–738
87. Lui C, Lee K, Nelson CM (2012) Matrix compliance and RhoA direct the differentiation of mammary progenitor cells. Biomech Model Mechanobiol 11:1241–1297
88. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, Sahai E (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15:637–646